Murray valley encephalitis

disease
On this page

Also known as Australian encephalitisAustralian X diseaseMurray Valley encephalitis virus caused disease or disorderMurray Valley encephalitis virus disease or disorderMurray Valley encephalitis virus infectious disease

Summary

Murray valley encephalitis (MONDO:0001137) is a disease. A subtype of Flaviviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameMurray valley encephalitis
Mondo IDMONDO:0001137
DOIDDOID:10842
ICD-10-CMA83.4
ICD-111040970454
SNOMED CT66454007
UMLSC0153066
MedGen509134
Is cancer (heuristic)no

Also known as: Australian encephalitis · Australian X disease · Murray Valley encephalitis virus caused disease or disorder · Murray Valley encephalitis virus disease or disorder · Murray Valley encephalitis virus infectious disease

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseaseviral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › Murray valley encephalitis

Related subtypes (9): Powassan encephalitis, West Nile fever, dengue disease, pestivirus infectious disease, st. Louis encephalitis, Kyasanur forest disease, Omsk hemorrhagic fever, Zika virus infectious disease, yellow fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.